A practical reference on chelation stability: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-15 and is reviewed periodically as new material appears.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-lysine and a copper(II) ion. The peptide sequence is conventionally written as Gly-His-Lys, abbreviated GHK. Copper binds through the imidazole nitrogen of histidine, the alpha-amino group, and a deprotonated amide nitrogen, producing a square-planar geometry. The complex carries a net positive charge near physiological pH and is intensely blue in aqueous solution. The metal-free peptide is often written simply as GHK, while the copper-bound form is written GHK-Cu.
The compound was first isolated from human plasma by the biochemist Loren Pickart in 1973. Early work identified it as a factor that altered the behavior of cultured liver cells, and later studies linked it to connective tissue and wound-related processes. Reported plasma concentrations fall markedly between roughly age twenty and age sixty, a pattern that generated interest in copper peptide biology. Whether that decline has functional consequences remains an open question, because differences observed across age groups do not by themselves establish causation. Research interest later expanded into cosmetic and tissue-culture settings.
Solid GHK-Cu is usually supplied as a lyophilized powder and is kept cold and dry. Moisture, light, and repeated temperature cycling shorten its useful life in the laboratory. In aqueous solution the complex undergoes slow hydrolysis of the peptide backbone and gradual loss of coordinated copper. Buffers containing strong chelators, such as EDTA, compete for the metal and strip it from the peptide. Working solutions are therefore prepared shortly before use, and leftover liquid is not returned to the stock container.
Identity and purity are established with a combination of chromatographic and spectroscopic techniques. Reversed-phase high-performance liquid chromatography separates the intact complex from peptide fragments and free copper, and the elution profile yields a purity estimate. Mass spectrometry gives the mass of the intact species and exposes degradation products. Ultraviolet-visible spectroscopy displays a broad absorption band in the visible region that is characteristic of the copper center. Nuclear magnetic resonance is less informative here, because the paramagnetic metal broadens signals and complicates spectral interpretation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22CuN6O4 as the complex | Free peptide is C14H24N6O4 |
| Molecular weight | About 402 g/mol | Free peptide is about 340 g/mol |
| Appearance | Blue solid or blue solution | Color from copper d-d transitions |
| Solubility class | Water-soluble; poor in nonpolar solvents | Ionic character favors aqueous media |
| Common synonyms | Copper tripeptide-1; glycyl-L-histidyl-L-lysine copper | INCI listing uses copper tripeptide-1 |
Handling practices for the solid material emphasise low temperature and dryness. The lyophilised or powdered form is typically kept at refrigerator or freezer temperatures together with a desiccant. Working solutions are often prepared fresh, because repeated freeze-thaw cycles and extended storage may alter the complex. Glass or inert plastic containers are preferred over materials that could leach metal ions into the preparation. Such practices follow general peptide conventions rather than substance-specific regulations.
Analytical verification commonly relies on high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Spectroscopic methods such as UV-visible absorption and electron paramagnetic resonance can probe the metal centre itself, since the d9 configuration of copper(II) produces characteristic signals. Elemental analysis or plasma-based techniques quantify copper content. Because each method reports a different aspect of the same sample, purity figures are most meaningful when the technique and its detection wavelength are stated alongside the value.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
==== 12 Hour Operational Ration Pack ==== The British Armed Forces' 12 hour operational ration pack (ORP) is designed for patrolling for durations of 4–12 hours and is suitable for remote guard posts, drivers and as a supplement to normal rations for where daily calorie expenditure is likely to exceed 6000 kcal (25,120 kJ), for instance, troops undergoing arduous duties. The 12 hour ORP contains a main meal packed in a retort pouch, a number of snack items, drink powders and a flameless ration heater (FRH). However it does not contain any hot beverage items. There are 10 menu choices including one vegetarian.
Diatomite forms by the accumulation of the amorphous silica (opal, SiO2·nH2O) remains of dead diatoms (microscopic single-celled algae) in lake sediment or marine sediments. The fossil remains consist of a pair of symmetrical shells or frustules. Marine diatomites are found in association with a wide variety of other rock types but lacustrine diatomites are almost always associated with volcanic rock. Diatomaceous chert consists of diatomite that has been cemented with silica. Diatoms are able to extract silica from water that is less than 1% saturated in amorphous silica (saturation index (SI): -2). Their frustules remain undissolved because they are surrounded by an organic matrix. Clay minerals may also precipitate on the frustules and protect them from dissolution in sea water. When the diatom dies, the frustule is stripped of its organic layer and exposed to sea water. As a result, only 1% to 10% of frustules survive long enough to be buried under sediments and some of this is dissolved within the sediments. Only an estimated 0.05% to 0.15% of the original amount of silica produced by diatoms is preserved in the sedimentary record.
== Usage as doping product == As a performance-enhancing drug, EPO has been banned since the early 1990s, but a test was not available until the 2000 Summer Olympics. Before this test was available, some athletes were sanctioned after confessing to having used EPO, for example in the Festina affair, when a car with doping products for the Festina cycling team was found. The first doping test in cycling was used in the 2001 La Flèche Wallonne. The first rider to test positive in that race was Bo Hamburger, although he was later acquitted because his B-sample was not conclusive. The U.S. Postal Service Pro Cycling Team, under the leadership of Lance Armstrong and Johan Bruyneel, ran a sophisticated doping program that lasted for many years during the late 1990s and early 2000s. Erythropoietin was a common substance used by the cyclists. Studies of the effectiveness of EPO in cycling consistently associate EPO with an increase in subjects' maximal aerobic capacity, but yield mixed results as to the drug's effects on submaximal aerobic efforts. A 2007 study showed that EPO treatment led to a statistically significant improvement in cyclists' abilities to maintain a "submaximal" effort of about 80% of their pre-treatment aerobic maximum (VO2max). The study found that subjects treated with EPO saw increased VO2max values, and the amount of time they could maintain their initial submaximal effort also increased.
Sources: en.wikipedia.org
=== Discovery === Ritonavir (initially designated as ABT-538) was developed through the systematic structural modification of A-80987, a moderately potent, symmetry-based HIV protease inhibitor. While A-80987 demonstrated good oral bioavailability, its clinical utility was limited by a very short circulating half-life. This rapid clearance was primarily driven by the oxidative metabolism (specifically N-oxidation) of its pyridyl end groups by cytochrome P450 enzymes in the liver and intestine.
In all cases where β+ decay (positron emission) of a nucleus is allowed energetically, so too is electron capture allowed. This is a process during which a nucleus captures one of its atomic electrons, resulting in the emission of a neutrino:
=== Thrombolysis, stenting and surgery === Thrombolysis, stenting and surgery are not used as widely as anticoagulation or antiplatelet drugs. These treatments are invasive, and are typically reserved for situations where symptoms worsen despite medical treatment, or where medical treatment may be unsafe (e.g. an unacceptable bleeding tendency). Thrombolysis is enzymatic destruction of blood clots. This is achieved by the administration of a drug (such as urokinase or alteplase) that activates plasmin, an enzyme that occurs naturally in the body and digests clots when activated. Thrombolysis is an accepted treatment for heart attacks and stroke unrelated to dissection. In cervical artery dissection, only small case series are available. The thrombolytic drug is administered either intravenously or during cerebral angiography through a catheter directly into the affected artery. The data indicates that thrombolysis is safe, but its place in the treatment of VAD is uncertain. Stenting involves the catheterization of the affected artery during angiography, and the insertion of a mesh-like tube; this is known as "endovascular therapy" (inside the blood vessel). This may be performed to allow the blood to flow through a severely narrowed vessel, or to seal off an aneurysm. However, it is unclear whether the technical success of the procedure translates into improved outcomes, as in both cases the problem often resolves spontaneously over time.
=== Mathematics === Cauchy problem, in partial differential equations Complex projective space (CPn), the projective space with respect to the field of complex numbers Mallows's Cp, a statistic used in model selection The field
Sources: en.wikipedia.org
It is the copper(II) complex of the tripeptide glycyl-L-histidyl-lysine, a sequence of three amino acids. The copper ion is held by the histidine imidazole, the terminal amino group, and an amide nitrogen. The bound form is distinct from the free peptide in charge, color, and stability.
Copper(II) complexes absorb light in the red part of the visible spectrum, so transmitted light appears blue. The absorption arises from electronic transitions within the copper d-orbitals, which are split by the surrounding ligands. The intensity and exact wavelength shift somewhat with pH, solvent, and ligand arrangement.
The free peptide and the copper-bound complex are studied as separate species and do not always behave the same way in assays. Some reported responses are attributed to copper delivery, while others are attributed to the peptide sequence itself. Which fraction drives a given observation is often unresolved in the published work.
Lyophilized material is normally held at about minus twenty degrees Celsius in a sealed, desiccated vial. Dissolved samples are less durable and are prepared fresh. Repeated freeze-thaw cycles are avoided.